STERIALS

The company is focused on clinical-stage cancer, developing T cell receptor (TCR) therapies based on its proprietary non-viral gene transfer platform and proprietary cancer mutation hotspot TCR library covering common tumors. It is currently conducting clinical trials in non-small cell lung cancer, colorectal cancer, endometrial cancer, pancreatic cancer, ovarian cancer, and cholangiocarcinoma. It is a Delaware-based company.